Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Short Interest Jumps 129.4%

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totaling 87,767 shares, a growth of 129.4% from the September 30th total of 38,253 shares. Based on an average trading volume of 28,905 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.9% of the shares of the stock are short sold.

Intensity Therapeutics Stock Up 1.8%

NASDAQ INTS traded up $0.06 during trading hours on Friday, hitting $3.40. The company had a trading volume of 16,111 shares, compared to its average volume of 20,242. The firm’s 50 day moving average is $3.77 and its 200 day moving average is $5.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. Intensity Therapeutics has a fifty-two week low of $3.00 and a fifty-two week high of $28.75. The company has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.95 and a beta of 2.81.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Sell-side analysts anticipate that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on INTS shares. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. Finally, HC Wainwright upped their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Intensity Therapeutics has an average rating of “Moderate Buy” and an average target price of $7.00.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.